Rituxan® (rituximab)

BL 103705 [BL 103737]

Rituxan® (rituximab)

BL 103705 [BL 103737]

U.S. License Holder:

Genentech [IDEC Pharmaceuticals Corp.]

Date of License:

November-26-1997

Last Update:

Dec-15-2024

approved_indications FDA-Approved Indications

BL 103705: RITUXAN (rituximab) is a CD20-directed cytolytic antibody indicated for the treatment of:

Adult Patients with Non-Hodgkin's Lymphoma (NHL): Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent; Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy; Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens;

Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL): Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy.

Adult Patients with Chronic Lymphocytic Leukemia (CLL): Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC);

Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies;

Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids;

Moderate to severe Pemphigus Vulgaris (PV) in adult patients.

BL 103737: RITUXAN (rituximab) is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma.

approved_indications aBLA / 505(b)(2) Activity

aBLA / 505(b)(2) Approved by FDA

Truxima® (CT-P10): Celltrion/Teva (November-2018) Ruxience®: Pfizer (July-2019) Riabni (ABP 798): Amgen/Allergan (December-2020)

aBLA / 505(b)(2) Accepted by FDA

Rixathon®: Sandoz (September-2017; Complete Response Letter May-2018) DRL_RI: Dr. Reddy's / Fresenius Kabi (July-2023, Complete Response Letter April-2024)

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In Canada

Riximyo® (Sandoz) (April-2020)
Ruxience® (Pfizer) (May-2020)
Truxima® (Teva) (April-2019)

Biosimilars Approved In The E.U.

Blitzima (Celltrion) (July-2017)
Ritemvia (Celltrion) (July-2017)
Rituzena (Celltrion) (July-2017)
Rixathon® (Sandoz) (June-2017)
Riximyo® (Sandoz) (June-2017)
Ruxience® (Pfizer) (April-2020)
Truxima® (Celltrion) (February-2017)

Biosimilars Approved In Australia

Riximyo® (Sandoz) (November-2017)
Ruxience (Pfizer) (March-2021)
Truxima® / Ritemvia® / Rituzena® / Tuxella® (Celltrion) (April-2018)

Biosimilars Approved In South Korea

Truxima® (CT P10) (Celltrion) (November-2016)

approved_indications Inter Partes Review Proceedings

PTAB Portal

IPR Case No(s):

IPR2015-00415

U.S. Patent No.
7,820,161 (Treatment Of Autoimmune Diseases)

Patent Owner
Biogen Inc.; Biogen IDEC, Inc.; Genentech, Inc.

Petitioner(s)
Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharmaceuticals Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-12

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Petitioner Requested Adverse Judgment After Institution)

IPR Status
IPR Terminated After Institution (Petitioner Requested Adverse Judgment)

IPR2015-00417

U.S. Patent No.
7,976,838 (Therapy of Autoimmune Disease in a Patient With an Inadequate Response to a TNF-alpha Inhibitor)

Patent Owner
Genentech, Inc.

Petitioner(s)
Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharmaceuticals Inc.

§ 102 Challenge
Y: Claims 1-14

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
N

§ 103 challenge
Y: Claims 1-14

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Petitioner Requested Adverse Judgment After Institution)

IPR Status
IPR Terminated After Institution (Petitioner Requested Adverse Judgment)

IPR2015-00418

U.S. Patent No.
8,329,172 (Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody)

Patent Owner
Biogen Inc.; Biogen IDEC, Inc.

Petitioner(s)
Boehringer Ingelheim International GmbH; Boehringer Ingelheim Pharmaceuticals Inc.

§ 102 Challenge
Y: Claim 1

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
N

§ 103 challenge
Y: Claim 1

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2015-01733

U.S. Patent No.
7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor)

Patent Owner
Genentech, Inc.

Petitioner(s)
Celltrion, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-14

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Terminated Prior to Institution Decision

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Petitioner Requested Dismissal Prior to Institution Decision)

IPR Status
IPR Terminated Prior to Institution Decision (Petitioner Requested Dismissal Without Prejudice)

IPR2015-01744

U.S. Patent No.
7,820,161 (Treatment of Autoimmune Diseases)

Patent Owner
Biogen Inc.; Biogen IDEC, Inc.; Genentech, Inc.

Petitioner(s)
Celltrion, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1, 2, 5, 6, 9, 10

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Terminated Prior to Institution Decision

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Petitioner Requested Dismissal Prior to Institution Decision)

IPR Status
IPR Terminated Prior to Institution Decision (Petitioner Requested Dismissal Without Prejudice)

IPR2016-01614

U.S. Patent No.
7,820,161 (Treatment of Autoimmune Diseases)

Patent Owner
Biogen Inc.; Genentech, Inc.

Petitioner(s)
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH f/k/a Ivax International GmbH

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-12

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
18-1885; 18-1924 (consolidated with 18-1885)

IPR Status
Final Written Decision (No Instituted Claim Found Unpatentable); Federal Circuit Appeal 18-1924 Dismissed; Federal Circuit Appeal 18-1885 Voluntarily Dismissed

IPR2016-01667

U.S. Patent No.
7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor)

Patent Owner
Genentech, Inc.

Petitioner(s)
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH f/k/a Ivax International GmbH

§ 102 Challenge
Y: Claims 1-5, 7-14

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
N

§ 103 challenge
Y: Claims 1-14

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted; Request for Rehearing Denied

IPR2017-01093

U.S. Patent No.
8,329,172 (Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody)

Patent Owner
Biogen Inc.

Petitioner(s)
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH

§ 102 Challenge
Y: Claim 1

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
N

§ 103 challenge
Y: Claim 1

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2017-01094

U.S. Patent No.
8,557,244 (Treatment of Aggressive Non-Hodgkins Lymphoma with Anti-CD20 Antibody)

Patent Owner
Biogen Inc.

Petitioner(s)
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-2

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted; Petitioner Request for Rehearing of Institution Decision Denied

IPR2017-01095

U.S. Patent No.
9,296,821 (Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibodies)

Patent Owner
Biogen Inc.

Petitioner(s)
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH

§ 102 Challenge
Y: Claims 1-6

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y: Claims 1-6

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
19-1253

IPR Status
Petitioner Request for Rehearing of Institution Decision Denied; Final Written Decision (All Instituted Claims Found Unpatentable); Federal Circuit Appeal Terminated as to Celltrion Due to Settlement, Voluntarily Dismissed as to US as Intervenor

IPR2017-01115

U.S. Patent No.
7,820,161 (Treatment of Autoimmune Diseases)

Patent Owner
Biogen Inc.; Genentech, Inc.

Petitioner(s)
Pfizer Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-12

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
18-1885; 18-1924 (consolidated with 18-1885)

IPR Status
Joined with IPR2016-01614; Final Written Decision (No Instituted Claim Found Unpatentable); Federal Circuit Appeal 18-1924 Dismissed; Federal Circuit Appeal 18-1885 Voluntarily Dismissed

IPR2017-01166

U.S. Patent No.
8,329,172 (Combination Therapies For B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody)

Patent Owner
Biogen Inc.

Petitioner(s)
Pfizer Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claim 1

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted; Petitioner's Request for Rehearing Withdrawn

IPR2017-01167

U.S. Patent No.
8,557,244 (Treatment of Aggressive Non-Hodgkins Lymphoma with Anti-CD20 Antibody)

Patent Owner
Biogen Inc.

Petitioner(s)
Pfizer Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-2

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted; Petitioner's Request for Rehearing Denied

IPR2017-01168

U.S. Patent No.
8,821,873 (Treatment of Diffuse Large-Cell Lymphoma With Anti-CD20 Antibody)

Patent Owner
Biogen Inc.

Petitioner(s)
Pfizer Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-5

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Final Written Decision Issued
Y

Federal Circuit Appeal(s)
19-1364

IPR Status
Final Written Decision (All Instituted Claims Found Unpatentable); Federal Circuit Appeal Affirmed with USPTO Director as Intervenor, Pfizer Not Participating in Appeal

IPR2017-01227

U.S. Patent No.
7,682,612 (Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody)

Patent Owner
Biogen Inc.; Genentech, Inc.

Petitioner(s)
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH

§ 102 Challenge
N

§ 103 challenge
Y: Claims 23-35, 37-57

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2017-01229

U.S. Patent No.
8,206,711 (Treatment of Chronic Lymphocytic Leukemia Using Anti-CD20 Antibodies)

Patent Owner
Biogen Inc.; Genentech, Inc.

Petitioner(s)
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH

§ 102 Challenge
Y: Claims 1, 5, 7-9

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
N

§ 103 challenge
Y: Claims 1-9

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2017-01230

U.S. Patent No.
7,682,612 (Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody)

Patent Owner
Biogen Inc.; Genentech, Inc.

Petitioner(s)
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH

§ 102 Challenge
Y: Claims 1-7, 11-13, 15-18, 21-22, 59-60

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
N

§ 103 challenge
Y: Claims 1-13, 15-22, 58-60

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2017-01923

U.S. Patent No.
7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor)

Patent Owner
Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-14

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)

IPR Status
Terminated After Institution Due to Settlement

IPR2017-02036

U.S. Patent No.
7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor)

Patent Owner
Genentech, Inc.

Petitioner(s)
Sandoz, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-14

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2017-02042

U.S. Patent No.
7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor)

Patent Owner
Genentech, Inc.

Petitioner(s)
Sandoz, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-14

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2017-02126

U.S. Patent No.
7,682,612 (Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody)

Patent Owner
Biogen Inc.; Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-13, 15-35, 37-60

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2017-02127

U.S. Patent No.
8,206,711 (Treatment of Chronic Lymphocytic Leukemia Using Anti-CD20 Antibodies)

Patent Owner
Biogen Inc.; Genentech, Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-9

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2018-00086

U.S. Patent No.
8,545,843 (Treatment of Vasculitis)

Patent Owner
Biogen Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-12

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
N

IPR Status
IPR Not Instituted

IPR2018-00186

U.S. Patent No.
9,296,821 (Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibodies)

Patent Owner
Biogen Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
Y: Claims 4-6

Claim Types Challenged Under § 102
Method of Treatment

§ 102 Challenge Instituted
Y

§ 103 challenge
Y: Claims 1-6

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Joint Request to Terminate)

IPR Status
Terminated After Institution

IPR2018-00231

U.S. Patent No.
9,504,744 (Treatment of Diffuse Large-Cell Lymphoma with Anti-CD20 Antibody)

Patent Owner
Biogen Inc.

Petitioner(s)
Pfizer, Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-16

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Terminated Prior to Institution Decision

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Petitioner Requested Dismissal with Prejudice Prior to Institution Decision)

IPR Status
Terminated Prior to Institution Decision (Petitioner Requested Dismissal with Prejudice)

IPR2018-00285

U.S. Patent No.
8,329,172 (Combination Therapies For B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody)

Patent Owner
Biogen Inc.

Petitioner(s)
Pfizer Inc.

§ 102 Challenge
N

§ 103 challenge
Y: Claim 1

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)

IPR Status
Terminated After Institution Due to Settlement

IPR2018-01019

U.S. Patent No.
7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor)

Patent Owner
Genentech, Inc.

Petitioner(s)
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH

§ 102 Challenge
N

§ 103 challenge
Y: Claims 1-14

Claim Types Challenged Under § 103
Method of Treatment

§ 103 Challenge Instituted
Y; Joined with IPR2017-01923

Settled / Challenged Claims Disclaimed / Challenge Terminated
Y (Settled After Institution)

IPR Status
Joined with IPR2017-01923; Terminated After Institution Due to Settlement

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:17-cv-13507 (D.N.J.)

U.S. Patent Nos.
6,121,428 (Protein Recovery) 6,331,415 (Methods of Producing Immunoglobulins, Vectors and Transformed Host Cells for Use Therein) 6,489,447 (Protein Purification) 6,610,516 (Cell Culture Process) 6,620,918 (Separation of Polypeptide Monomers) 6,870,034 (Protein Purification) 7,381,560 (Expression and Use of Anti-CD20 Antibodies) 7,485,704 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,807,799 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,820,161 (Treatment of Autoimmune Diseases) 7,923,221 (Methods of Making Antibody Heavy and Light Chains having Specificity for a Desired Antigen) 7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor) 8,206,711 (Treatment of Chronic Lymphocytic Leukemia Using Anti-CD20 Antibodies) 8,314,225 (Heavy Chain Mutant Leading to Improved Immunoglobulin Production) 8,329,172 (Combination Therapies For B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody) 8,512,983 (Production of Proteins in Glutamine-Free Cell Culture Media) 8,545,843 (Treatment of Vasculitis) 8,557,244 (Treatment of Aggressive Non-Hodgkins Lymphoma with Anti-CD20 Antibody) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 8,710,196 (Protein Purification) 8,821,873 (Treatment of Diffuse Large-Cell Lymphoma With Anti-CD20 Antibody) 9,296,821 (Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibodies) 9,504,744 (Treatment of Diffuse Large-Cell Lymphoma with Anti-CD20 Antibody) 9,714,293 (Production of Proteins in Glutamine-free Cell Culture Media)

Plaintiffs
Biogen, Inc.; City of Hope; Genentech, Inc.

Defendants
Sandoz GmbH; Sandoz Inc.; Sandoz International GmbH

Status
Joint Stipulation of Dismissal

BPCIA
Y

1:18-cv-00574 (D.N.J.)

U.S. Patent Nos.
6,121,428 (Protein Recovery) 6,242,177 (Methods and Compositions for Secretion of Heterologous Polypeptides) 6,331,415 (Methods of Producing Immunoglobulins, Vectors and Transformed Host Cells for Use Therein) 6,417,335 (Protein Purification) 6,455,043 (Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody) 6,489,447 (Protein Purification) 6,586,206 (Methods for Making Recombinant Proteins Using Apoptosis Inhibitors) 6,610,516 (Cell Culture Process) 6,620,918 (Separation of Polypeptide Monomers) 6,716,602 (Metabolic Rate Shifts in Fermentations Expressing Recombinant Proteins) 7,381,560 (Expression and Use of Anti-CD20 Antibodies) 7,390,660 (Methods for Growing Mammalian Cells In Vitro) 7,485,704 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,682,612 (Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody) 7,807,799 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,820,161 (Treatment of Autoimmune Diseases) 7,923,221 (Methods of Making Antibody Heavy and Light Chains having Specificity for a Desired Antigen) 7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor) 8,044,017 (Protein Purification) 8,206,711 (Treatment of Chronic Lymphocytic Leukemia Using Anti-CD20 Antibodies) 8,329,172 (Combination Therapies For B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody) 8,357,301 (Chromatography Equipment Characterization) 8,460,895 (Method for Producing Recombinant Proteins with a Constant Content of pCO2 in the Medium) 8,512,983 (Production of Proteins in Glutamine-Free Cell Culture Media) 8,545,843 (Treatment of Vasculitis) 8,557,244 (Treatment of Aggressive Non-Hodgkins Lymphoma with Anti-CD20 Antibody) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 8,633,302 (Variable Tangential Flow Filtration) 8,710,196 (Protein Purification) 8,771,988 (Protein Expression from Multiple Nucleic Acids) 8,821,873 (Treatment of Diffuse Large-Cell Lymphoma With Anti-CD20 Antibody) 8,822,655 (Pre-filtration Adjustment of Buffer Solutes) 9,047,438 (Chromatography Equipment Characterization) 9,080,183 (Promoter) 9,296,821 (Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibodies) 9,428,548 (Enhanced Protein Purification Through a Modified Protein A Elution) 9,428,766 (Protein Expression from Multiple Nucleic Acids) 9,487,809 (Decreasing Lactate Level and Increasing Polypeptide Production by Downregulating the Expression of Lactate Dehydrogenase and Pyruvate Dehydrogenase Kinase) 9,504,744 (Treatment of Diffuse Large-Cell Lymphoma with Anti-CD20 Antibody) 9,714,293 (Production of Proteins in Glutamine-free Cell Culture Media)

Plaintiffs
Biogen, Inc.; City of Hope; Genentech, Inc.; Hoffmann-La Roche Inc.

Defendants
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH; Teva Pharmaceuticals USA, Inc.

Status
Settled

BPCIA
Y

1:18-cv-11553 (D.N.J.)

U.S. Patent Nos.
6,331,415 (Methods of Producing Immunoglobulins, Vectors and Transformed Host Cells for Use Therein) 6,489,447 (Protein Purification) 6,610,516 (Cell Culture Process) 6,620,918 (Separation of Polypeptide Monomers) 7,381,560 (Expression and Use of Anti-CD20 Antibodies) 7,485,704 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,807,799 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,820,161 (Treatment of Autoimmune Diseases) 7,923,221 (Methods of Making Antibody Heavy and Light Chains having Specificity for a Desired Antigen) 7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor) 8,206,711 (Treatment of Chronic Lymphocytic Leukemia Using Anti-CD20 Antibodies) 8,329,172 (Combination Therapies For B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody) 8,545,843 (Treatment of Vasculitis) 8,557,244 (Treatment of Aggressive Non-Hodgkins Lymphoma with Anti-CD20 Antibody) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 8,821,873 (Treatment of Diffuse Large-Cell Lymphoma With Anti-CD20 Antibody) 9,296,821 (Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibodies) 9,504,744 (Treatment of Diffuse Large-Cell Lymphoma with Anti-CD20 Antibody)

Plaintiffs
Biogen, Inc.; City of Hope; Genentech, Inc.; Hoffmann-La Roche Inc.

Defendants
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH; Teva Pharmaceuticals USA, Inc.

Status
Settled

BPCIA
Y

1:23-cv-22485 (D.N.J.)

U.S. Patent Nos.
7,485,704 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor) 8,460,895 (Method for Producing Recombinant Proteins with a Constant Content of pCO2 in the Medium) 8,512,983 (Production of Proteins in Glutamine-Free Cell Culture Media) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 9,714,293 (Production of Proteins in Glutamine-free Cell Culture Media) 10,017,732 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,336,983 (Method for Increasing the Specific Production Rate of Eukaryotic Cells) 10,450,379 (Method for Treating Joint Damage) 10,654,940 (Method for Treating Joint Damage) 10,662,237 (Method to Improve Virus Filtration Capacity) 10,676,710 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,759,866 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 10,829,732 (Cell Culture Compositions with Antioxidants and Methods for Polypeptide Production) 10,982,003 (Production of Proteins in Glutamine-Free Cell Culture Media)

Plaintiffs
Genentech, Inc.; Biogen, Inc.; Hoffmann-La Roche Inc.

Defendants
Dr. Reddy's Laboratories, Inc.; Dr. Reddy's Laboratories, Ltd.; Dr. Reddy's Laboratories, SA; Fresenius Kabi Deutschland GmbH; Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi USA, LLC

Status
Settled

BPCIA
Y

3:08-cv-04909 (N.D. Cal.)

U.S. Patent Nos.
5,849,522 (Enhancer for Eukaryotic Expression Systems) 6,218,140 (Enhancer for Eukaryotic Expression Systems)

Plaintiffs
Sanofi-Aventis Deutschland GmbH; Sanofi-Aventis U.S. LLC; Sanofi-Aventis U.S. Inc.

Defendants
Biogen IDEC, Inc.; Genentech, Inc.

Federal Circuit Appeal(s)
12-1454

Status
Case Terminated

BPCIA
N

3:09-cv-04919 (N.D. Cal.)

U.S. Patent Nos.
5,849,522 (Enhancer for Eukaryotic Expression Systems) 6,218,140 (Enhancer for Eukaryotic Expression Systems)

Plaintiffs
Sanofi-Aventis Deutschland GmbH

Defendants
Biogen IDEC, Inc.; Genentech, Inc.

Federal Circuit Appeal(s)
12-1454

Status
Case Terminated

BPCIA
N

4:18-cv-00276 (N.D. Cal.)

U.S. Patent Nos.
6,331,415 (Methods of Producing Immunoglobulins, Vectors and Transformed Host Cells for Use Therein) 6,417,335 (Protein Purification) 6,455,043 (Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody) 6,489,447 (Protein Purification) 6,586,206 (Methods for Making Recombinant Proteins Using Apoptosis Inhibitors) 6,610,516 (Cell Culture Process) 6,620,918 (Separation of Polypeptide Monomers) 6,716,602 (Metabolic Rate Shifts in Fermentations Expressing Recombinant Proteins) 7,390,660 (Methods for Growing Mammalian Cells In Vitro) 7,485,704 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,682,612 (Treatment of Hematologic Malignancies Associated with Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody) 7,807,799 (Reducing Protein A Leaching During Protein A Affinity Chromatography) 7,820,161 (Treatment of Autoimmune Diseases) 7,923,221 (Methods of Making Antibody Heavy and Light Chains having Specificity for a Desired Antigen) 7,976,838 (Therapy of Autoimmune Disease in a Patient with an Inadequate Response to a TNF-alpha Inhibitor) 8,044,017 (Protein Purification) 8,206,711 (Treatment of Chronic Lymphocytic Leukemia Using Anti-CD20 Antibodies) 8,329,172 (Combination Therapies For B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibody) 8,357,301 (Chromatography Equipment Characterization) 8,460,895 (Method for Producing Recombinant Proteins with a Constant Content of pCO2 in the Medium) 8,512,983 (Production of Proteins in Glutamine-Free Cell Culture Media) 8,545,843 (Treatment of Vasculitis) 8,557,244 (Treatment of Aggressive Non-Hodgkins Lymphoma with Anti-CD20 Antibody) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 8,633,302 (Variable Tangential Flow Filtration) 8,710,196 (Protein Purification) 8,771,988 (Protein Expression from Multiple Nucleic Acids) 8,821,873 (Treatment of Diffuse Large-Cell Lymphoma With Anti-CD20 Antibody) 8,822,655 (Pre-filtration Adjustment of Buffer Solutes) 9,047,438 (Chromatography Equipment Characterization) 9,080,183 (Promoter) 9,296,821 (Combination Therapies for B-Cell Lymphomas Comprising Administration of Anti-CD20 Antibodies) 9,428,548 (Enhanced Protein Purification Through a Modified Protein A Elution) 9,428,766 (Protein Expression from Multiple Nucleic Acids) 9,487,809 (Decreasing Lactate Level and Increasing Polypeptide Production by Downregulating the Expression of Lactate Dehydrogenase and Pyruvate Dehydrogenase Kinase) 9,504,744 (Treatment of Diffuse Large-Cell Lymphoma with Anti-CD20 Antibody) 9,714,293 (Production of Proteins in Glutamine-free Cell Culture Media)

Plaintiffs
Celltrion Healthcare Co., Ltd.; Celltrion, Inc.; Teva Pharmaceuticals International GmbH; Teva Pharmaceuticals USA, Inc.

Defendants
Biogen, Inc.; City of Hope; Genentech, Inc.; Hoffmann-La Roche Inc.

Federal Circuit Appeal(s)
18-2161 (Consolidated with 18-2160; 18-2160 is Lead Appeal)

Status
Dismissed for Failure to State a Claim; Federal Circuit Appeal Voluntarily Dismissed

BPCIA
Y

Related News

Spotlight On: Biosimilar Litigations
April Breyer Menon Ha Kung Wong
November 30, 2024
Spotlight On: Rituxan® (rituximab) / Truxima® (rituximab-abbs) / Ruxience® (rituximab-pvvr) / Riabni™ (rituximab-arrx)
April Breyer Menon Corinne E. Atton Joyce L. Nadipuram Robert S. Schwartz, Ph.D.
November 30, 2024
Venable’s BiologicsHQ Monthly Injection – September 2024
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
October 11, 2024
Venable’s BiologicsHQ Monthly Injection – July 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
August 10, 2024
Venable’s BiologicsHQ Monthly Injection – June 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
July 9, 2024
Venable’s BiologicsHQ Monthly Injection – May 2024
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
June 11, 2024
Venable’s BiologicsHQ Monthly Injection – April 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
May 16, 2024
Genentech and Dr. Reddy’s Settle BPCIA Litigation Against Proposed Rituxan Biosimilar DRL_RI
Robert S. Schwartz, Ph.D.
April 15, 2024
Venable’s BiologicsHQ Monthly Injection – March 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
April 10, 2024
Venable’s BiologicsHQ Monthly Injection – February 2024
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
March 13, 2024
Venable’s BiologicsHQ Monthly Injection – January 2024
Monica Chou Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
February 13, 2024
Venable’s BiologicsHQ Monthly Injection – December 2023
Damineh Morsali, Ph.D. Monica Chou Robert S. Schwartz, Ph.D.
January 13, 2024
BPCIA Complaint Against Proposed Rituxan® Biosimilar DRL_RI Filed
Monica Chou Robert S. Schwartz, Ph.D.
December 13, 2023
Venable’s BiologicsHQ Monthly Injection – September 2023
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
October 16, 2023
Venable’s BiologicsHQ Monthly Injection – August 2023
Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
September 12, 2023
Venable’s BiologicsHQ Monthly Injection – July 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
August 15, 2023
Venable’s BiologicsHQ Monthly Injection – June 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
July 15, 2023
Venable’s BiologicsHQ Monthly Injection – May 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
June 13, 2023
Venable’s BiologicsHQ Monthly Injection – April 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
May 8, 2023
Venable’s BiologicsHQ Monthly Injection – March 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
April 10, 2023
The State of Biosimilars in 2023
April Breyer Menon Ha Kung Wong
March 17, 2023
Venable’s BiologicsHQ Monthly Injection – February 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
March 15, 2023
Venable’s BiologicsHQ Monthly Injection – January 2023
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
February 9, 2023
Venable’s BiologicsHQ Monthly Injection – December 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
January 12, 2023
Venable’s BiologicsHQ Monthly Injection – November 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
December 14, 2022
Venable’s BiologicsHQ Monthly Injection – October 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
November 14, 2022
Venable’s BiologicsHQ Monthly Injection – September 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
October 11, 2022
Venable’s BiologicsHQ Monthly Injection – August 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
September 8, 2022
Venable’s BiologicsHQ Monthly Injection – July 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
August 5, 2022
Venable’s BiologicsHQ Monthly Injection – June 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
July 8, 2022
Venable’s BiologicsHQ Monthly Injection – May 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
June 7, 2022
Venable’s BiologicsHQ Monthly Injection – April 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
May 9, 2022
Venable’s BiologicsHQ Monthly Injection – March 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
April 18, 2022
Venable’s BiologicsHQ Monthly Injection – February 2022
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
March 8, 2022
Venable’s BiologicsHQ Monthly Injection – October 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
November 10, 2021
Venable’s BiologicsHQ Monthly Injection – September 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
October 12, 2021
Venable’s BiologicsHQ Monthly Injection – August 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D.
September 8, 2021
Venable’s BiologicsHQ Monthly Injection – July 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
August 11, 2021
Venable’s BiologicsHQ Monthly Injection – June 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
July 13, 2021
Venable’s BiologicsHQ Monthly Injection – May 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
June 17, 2021
Venable’s BiologicsHQ Monthly Injection – April 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
May 12, 2021
Venable’s BiologicsHQ Monthly Injection – March 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
April 7, 2021
Venable’s BiologicsHQ Monthly Injection – February 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
March 9, 2021
Venable’s BiologicsHQ Monthly Injection – January 2021
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
February 8, 2021
Venable’s BiologicsHQ Monthly Injection – December 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
January 12, 2021
Venable’s BiologicsHQ Monthly Injection – November 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
December 9, 2020
Venable’s BiologicsHQ Monthly Injection – October 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
November 9, 2020
Venable’s BiologicsHQ Monthly Injection – September 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
October 8, 2020
Venable’s BiologicsHQ Monthly Injection – August 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
September 9, 2020
Venable’s BiologicsHQ Monthly Injection – July 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
August 10, 2020
Venable’s BiologicsHQ Monthly Injection – June 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
July 9, 2020
Venable’s BiologicsHQ Monthly Injection – May 2020
April Breyer Menon Damineh Morsali, Ph.D. Robert S. Schwartz, Ph.D. Ha Kung Wong
June 8, 2020
Venable’s BiologicsHQ Monthly Injection – April 2020
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D. Ha Kung Wong
May 6, 2020
Venable’s BiologicsHQ Monthly Injection – March 2020
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D. Ha Kung Wong
April 8, 2020
Venable’s BiologicsHQ Monthly Injection – February 2020
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D. Ha Kung Wong
March 12, 2020
Venable’s BiologicsHQ Monthly Injection – January 2020
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D. Ha Kung Wong
February 6, 2020
Venable’s BiologicsHQ Monthly Injection – December 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D. Ha Kung Wong
January 7, 2020
Venable’s BiologicsHQ Monthly Injection – November 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
December 9, 2019
Venable’s BiologicsHQ Monthly Injection – October 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D. Ha Kung Wong
November 11, 2019
Venable’s BiologicsHQ Monthly Injection – September 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
October 8, 2019
Venable’s BiologicsHQ Monthly Injection – August 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
September 9, 2019
Venable’s BiologicsHQ Monthly Injection – July 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
August 6, 2019
Venable’s BiologicsHQ Monthly Injection – June 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
July 9, 2019
Venable’s BiologicsHQ Monthly Injection – May 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
June 6, 2019
Venable’s BiologicsHQ Monthly Injection – April 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
May 7, 2019
Venable’s BiologicsHQ Monthly Injection – March 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
April 5, 2019
Venable’s BiologicsHQ Monthly Injection – February 2019
April Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
March 6, 2019
Venable’s BiologicsHQ Monthly Injection – January 2019
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
February 11, 2019
Venable’s BiologicsHQ Monthly Injection – December 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
January 9, 2019
Venable’s BiologicsHQ Monthly Injection – November 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
December 11, 2018
Venable’s BiologicsHQ Monthly Injection – October 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
November 12, 2018
Venable’s BiologicsHQ Monthly Injection – August 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
September 6, 2018
Venable’s BiologicsHQ Monthly Injection – July 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
August 3, 2018
Venable’s BiologicsHQ Monthly Injection – June 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
July 6, 2018
Venable’s BiologicsHQ Monthly Injection – May 2018
April M. Breyer Menon Joseph K. Yarsky Corinne E. Atton Robert S. Schwartz, Ph.D.
June 8, 2018
Venable’s BiologicsHQ Monthly Injection – April 2018
April M. Breyer Menon Corinne E. Atton Joseph K. Yarsky Robert S. Schwartz, Ph.D.
May 3, 2018
Venable’s BiologicsHQ Monthly Injection – March 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
April 6, 2018
Venable’s BiologicsHQ Monthly Injection – February 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
March 6, 2018
Venable’s BiologicsHQ Monthly Injection – January 2018
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
February 7, 2018
Venable’s BiologicsHQ Monthly Injection – December 2017
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
January 8, 2018
Venable’s BiologicsHQ Monthly Injection – November 2017
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
December 5, 2017
Venable’s BiologicsHQ Monthly Injection – October 2017
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
November 3, 2017
Venable’s BiologicsHQ Monthly Injection – August/September 2017
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
October 5, 2017
VIDEO: How Important is Inter Partes Review to Biosimilars?
Ha Kung Wong
August 9, 2017
Venable’s BiologicsHQ Monthly Injection – July 2017
April M. Breyer Menon Corinne E. Atton Robert S. Schwartz, Ph.D.
July 26, 2017

Methodology

Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha